Nasus Pharma LTD 6-K Filing
Ticker: NSRX · Form: 6-K · Filed: Dec 29, 2025 · CIK: 2029039
| Field | Detail |
|---|---|
| Company | Nasus Pharma LTD (NSRX) |
| Form Type | 6-K |
| Filed Date | Dec 29, 2025 |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 6-K filing submitted by Nasus Pharma LTD (ticker: NSRX) to the SEC on Dec 29, 2025.
How long is this filing?
Nasus Pharma LTD's 6-K filing is 1 pages with approximately 251 words. Estimated reading time is 1 minutes.
Where can I view the full 6-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 251 words · 1 min read · ~1 pages · Grade level 9.7 · Accepted 2025-12-29 08:00:48
Filing Documents
- form6-k.htm (6-K) — 20KB
- ex99-1.htm (EX-99.1) — 693KB
- ex99-2.htm (EX-99.2) — 114KB
- 0001493152-25-029210.txt ( ) — 4611KB
- nsrx-20250630.xsd (EX-101.SCH) — 35KB
- nsrx-20250630_cal.xml (EX-101.CAL) — 44KB
- nsrx-20250630_def.xml (EX-101.DEF) — 146KB
- nsrx-20250630_lab.xml (EX-101.LAB) — 274KB
- nsrx-20250630_pre.xml (EX-101.PRE) — 230KB
- form6-k_htm.xml (XML) — 723KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2025 (Report No. 2) Commission File Number: 001-42796 Nasus Pharma Ltd. Yigal Alon 65 Tel Aviv , Israel 6744317 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS This Report of Foreign Private Issuer on Form 6-K of Nasus Pharma Ltd. (the "Company") consists of the Company's: (i) Condensed Unaudited Interim Financial Statements as of and for the six months ended June 30, 2025, which are attached as Exhibit 99.1 hereto; and (ii) Management's Discussion and Analysis of Financial Condition and Results of Operations as of and for the six months ended June 30, 2025, which is attached as Exhibit 99.2 hereto. EXHIBIT INDEX Exhibit No. 99.1 Condensed Unaudited Interim Financial Statements as of and for the Six Months Ended June 30, 2025. 99.2 Management's Discussion and Analysis of Financial Condition and Results of Operation as of and for the Six Months Ended June 30, 2025. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NASUS PHARMA LTD. Date: December 29, 2025 By: /s/ Dan Teleman Name: Dan Teleman Title: Chief Executive Officer